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Background: To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy
in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD).
Methods: We performed a retrospective chart review of all patients with a diagnosis of NMO/NMOSD, supported
by a positive NMO-IgG testing, who were treated with methotrexate. A paired sample 2 tailed t test was used to
assess the annualized relapse rate during 18 months pre treatment with methotrexate to annualized relapse rate
18 months post treatment with methotrexate.
Results: We followed 9 patients meeting criteria for the study for a median of 62 months. All patients were
stabilized during attacks with high-dose steroids and/or plasmapheresis. Five patients (55.55%) were started on
methotrexate as an initial long-term immunosuppressant strategy. Three patients (33.33%) were initially treated with
pulse cyclophosphamide followed by methotrexate as a preplanned step-down strategy. One patient was started
on azathioprine prior to methotrexate. No patient had side effects requiring change in methotrexate therapy. Five
patients (55.55%) had stabilization of Expanded Disability Status Scale (EDSS) on methotrexate. One patient had a
small increase in EDSS due to concomitant illness. Three patients (33.33%) had methotrexate treatment failure
evidenced by worsening EDSS and ongoing relapses while on methotrexate, mandating a change in methotrexate
therapy. Average annualized relapse rate in the entire group comparing 18 months prior versus 18 months after
methotrexate treatment was reduced by an absolute value of 64% (3.11 vs 1.11). A paired t-test showed this
reduction was highly significant (p = .009).
Conclusion: In our experience, methotrexate is safe and possibly efficacious as a single long-term IS therapy along
with low dose corticosteroids that can reasonably be offered to patients with NMO/NMOSD.
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Neuromyelitis Optica (NMO) is a severe demyelinating
inflammatory disease of the central nervous system
characterized by recurrent attacks of myelitis and optic
neuritis [1-3]. Evidence suggests aquaporin 4-antibodies
(AQP4-ab) are primarily involved in the disease patho-
genesis [1,4,5]. AQP4-IgG is predominantly IgG1 and is
capable of activating complement, leading to blood brain
barrier disruption and destruction of astrocytic membranes
[6]. Recently it has also been shown that interleukin 6
(IL-6) plays a critical role in the pathogenesis of NMO [7,8].* Correspondence: dr.santosh7@gmail.com
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article, unless otherwise stated.It has been proposed that NMO/NMOSD requires
long-term treatment with immunosuppressant therapy
[9]. The largest case series suggest treatment of NMO/
NMOSD with immunosuppressant (IS) therapy with
rituximab, azathioprine and mycophenolate mofetile
[10-12]. In these retrospective studies, 14 (56%) of 25
patients were relapse free with rituximab after a median
follow up of 19 months, 37 (37%) of 99 patients were re-
lapse free with azathioprine after a median follow up of
24 months, and 14 (58%) of 24 patients were relapse free
with mycophenolate mofetile after a median follow up of
28 months [10-12]. A recent open label pilot study by
Pittock et al. has shown the use of eculizumab, a human-
ized monoclonal IgG that neutralizes complement proteinntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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over the period of 12 months [13]. The use of tocilizumab,
a humanized monoclonal antibody directed against the
IL-6 receptor, has been reported in a patient with severe
NMO with improvement in EDSS scores [14].
Minimal data exists on methotrexate as a long-term
treatment for NMO and NMOSD [15,16]. There are
multiple proposed mechanisms of action of methotrexate
to explain its efficacy in the attenuation of autoimmune
illness, including inhibition of purine metabolism, interfer-
ence with interleukin-1 beta binding to interleukin-1
receptors and interference with T-cell adhesion [17]. Con-
sidering patients with NMO/NMOSD will likely need
many years of immune suppression, the long-term safety
record of methotrexate makes this agent an attractive can-
didate for use in our clinic. We present our clinic ex-
perience of patients with NMO/NMOSD, treated with
methotrexate, overviewing 9 patients.
Methods
This retrospective analysis was approved by the Institu-
tional Review Board of Allegheny General Hospital. We
reviewed medical records of all patients with NMO
(2006 diagnostic criteria) or NMOSD (patients who had
one or more attacks of optic neuritis only, or transverse
myelitis only and who were NMO-IgG seropositive) who
were treated with methotrexate as IS therapy (2000 –
2012). For each patient we recorded 1) demographics; 2)
baseline clinical information; 3) treatment details (use of
methotrexate during remission and relapse, timing of
methotrexate initiation, concomitant corticosteroids,
CBC, liver function tests, adverse effects, timing and rea-
sons for discontinuation); 4) clinical course to last
follow-up (dates of attacks and EDSS during remission
and after relapses). A paired sample 2 tailed t test was
used to assess the annualized relapse rate during
18 months pre treatment with methotrexate to annualized
relapse rate 18 months post treatment with methotrexate.
Results
Demographic information for the nine patients studied,
EDSS scores and relapse summary information on the 9
patients are given in Table 1. Patients were followed for
a median of 62 months (mean = 82.89, SD = 43.779) and
were treated with methotrexate for a median of
29 months (mean = 40 months, SD = 20.005). 2 patients
(22%) presented with optic neuritis as an initial attack,
while 7 patients (78%) had myelitis initially, with 4 (57%)
of the myelitis onset cases remaining classified as
NMOSD throughout follow up (no optic neuritis). Pa-
tients were not retested for NMO IgG positivity follow-
ing treatment.
A summary of the treatment history of all 9 patients is
shown in Figure 1. All patients received high-dosecorticosteroids intravenously and/or plasmapheresis for
initial attacks or relapses and were otherwise continued
on low-dose corticosteroids (5–10 mg per day) along
with methotrexate therapy throughout the treatment
period. We treated patients with initial methotrexate
dosage of 7.5 mg once weekly with titration up to a
maximum of 17.5 mg once weekly, over several weeks.
All 9 patients received pulse intravenous methylprednis-
olone 500 mg twice daily for relapses with oral conver-
sion to 30 to 60 mg prednisone daily for 4–6 weeks
followed by a steroid weaning protocol in which prednis-
one was tapered to 20–30 mg for 4–6 weeks followed by
10–20 mg for 4–6 weeks and all 9 patients were then
maintained on low dose prednisone 5–10 mg for long
term (at least 6 months).
Relapses were defined based on clinical deterioration
of baseline symptoms or appearance of new symptoms
with change in EDSS, after infection had been ruled out,
hence all were true relapses. Five patients were initially
started on therapy with methotrexate after stabilization
with high-dose corticosteroids and/or plasmapheresis.
Three patients were also initially treated with pulse
cyclophosphamide (700 mg/M2) monthly for 6 months,
with a planned step down therapy to methotrexate. One
patient was started on azathioprine prior to methotrex-
ate. Patients who were continued on methotrexate for
their entire follow up (6/9, 67%) responded to treatment
as evidenced by stability or improvement on EDSS, ex-
cept 1 elderly patient had subtle and slow worsening of
gait over 36 months to add a single-point to her EDSS
score. Two of these patients had improvement of EDSS,
and three had unchanged EDSS. The visual subscores on
all the 9 patients were reviewed and we found that of 5
patients with optic neuritis and myelitis, 2 patients had
visual FSS (functional system scores) of 5 pre and post
methotrexate treatment (both patients had unilateral
blindness, with visual acuity of 20/20 in the other eye), 2
patients had visual FSS of 0, and 1 patient had visual
FSS of 1 with no change in visual subscores post treat-
ment with methotrexate.
Two of the patients who were continued on metho-
trexate had zero relapses, while three had 2 relapses
each, with these relapses being easily managed with full
recovery. Three patients (33.33%) were considered to be
treatment failures during treatment with methotrexate
due to multiple relapses (greater than or equal to three
each) and methotrexate was changed to rituximab
resulting in stabilization. None of the patients developed
any signs or symptoms of toxicity while on methotrexate
with complete blood count and liver function tests being
monitored every 8–12 weeks. Average annualized relapse
rate in the entire group comparing 18 months prior
versus 18 months after methotrexate treatment was re-
duced by an absolute value of 64% (3.11 vs 1.11). A
Table 1 Demographic information for the 9 patients studied, EDSS scores and relapse summary information
No. Age Gender Months
followed












1 40 M 62 Myelitis Myelitis 4 2 Stabilized on CTX* for 6 months, MTX** started as step down strategy, continued
during last visit.
54 6.5 1.5
2 71 F 13 Optic Neuritis Optic Neuritis
and Myelitis
10 0 MTX started initially, continued during last visit. 11 5.5 3
3 62 F 146 Myelitis Myelitis 5 1 MTX started initially, changed to MMF^^ briefly but due to S/E again started on MTX. 24 6.5 6.5
4 38 F 143 Myelitis Optic Neuritis
and Myelitis
7 0 Stabilized on CTX for 6 months, MTX started as step down strategy, continued
during last visit.
60 4 4
5 46 F 114 Optic Neuritis Optic Neuritis
and Myelitis
8 2 Initially on AZA*** then following relapses MTX started, continued during last visit. 29 4 4
6 74 F 62 Myelitis Myelitis 4 2 MTX started initially, continued during last visit. 52 4.5 5.5
7 54 F 85 Myelitis Optic Neuritis
and Myelitis
4 3 Stabilized on CTX for 6 months. MTX started as step down strategy, changed MTX
to MMF due to increasing relapses and later to RTX^^^.
24 2 4.5
8 57 M 59 Myelitis Myelitis 2 3 MTX started initially, MTX changed to MMF following continuing relapses and
later to RTX.
7 3.5 5.5
9 52 F 62 Myelitis Optic Neuritis
and Myelitis
3 4 MTX started initially, RTX following continued relapses. 52 2.5 2.5



















Figure 1 Depicting à summary of the treatment history,
relapses and treatment outcome of all 9 patients in the study.
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Discussion
This cohort represents the 3rd series of patients with
NMO/NMOSD studied retrospectively after treatment
with methotrexate and is comparable with data pub-
lished by Kitley et al. [15,16]. Statements concerning effi-
cacy in this scenario of a retrospective cohort are
scientifically weak, but are reasonably afforded some val-
idity given the lack of superior studies. The lack of re-
lapses or relapses with residual effects seen in several of
our patients is somewhat encouraging in this regard,
providing efficacy data on par with some previous case
series. We acknowledge significant selection bias as well
as the limitations of EDSS as an assessment tool in NMO.
Individual cases in our series can give clinicians insight
into patterns of relapse and progression seen in NMO.
For example, in patient 1 EDSS reached to 6.5 due to re-
lapses prior to starting MTX, at which point the patient
received treatment with high dose IV corticosteroids and
monthly pulse cyclophosphamide for 6 months with
planned step down strategy to methotrexate and main-
tenance low dose steroids. Improvement was seen stead-
ily over several months with documented improvementof EDSS to 1.5. EDSS improvement over many months
implies good response to cyclophosphamide, followed by
methotrexate and steroids over a protracted period.
Similarly patient 2 had 10 relapses prior to starting
methotrexate but had a sustained relapse free period
with improvement in EDSS following treatment with
methotrexate and low dose maintenance steroids. Fur-
thermore, overviewing our entire case series, although
complete freedom from relapse is a goal, it is not clear
whether or not relapse free status is needed to achieve
progression free status (some patients were not relapse
free but quickly responded to a single high dose cortico-
steroid pulse to return to baseline).
In patients with severe onset of NMO/NMOSD we
have tended to use therapeutic agents which have
already had reported success in reducing relapses (rather
than methotrexate which has been minimally used in
this disorder). We suspect that such patients are more
vulnerable to further severe attacks. Contra wise, in pa-
tients with mild onset, given the perceived need for
long-term immunosuppression in patients with NMO/
NMOSD, and given the excellent safety profile of metho-
trexate, we feel it is reasonable to attempt treatment
with methotrexate as initial therapy. We also used
methotrexate as a “step down” therapy from other treat-
ments, which are possibly more toxic (cyclophospha-
mide in 3 cases). Elderly patients, being perhaps more
susceptible to side effects of chronic immune suppres-
sion, may also be good candidates for initial therapy with
methotrexate. Reviewing the long-term safety data on
the handful of immunosuppressant agents commonly
used in NMO/NMOSD, we find methotrexate has an ex-
cellent safety profile. Safety data for long-term use of
mycophenolate mofetile, azathioprine, and rituximab
might be interpreted as inferior or less robust by com-
parison. Extensive experience with rheumatoid arthritis
and other autoimmune illness has provided an extensive
amount of safety data on methotrexate [18].
Available data from other cohort studies suggest ritux-
imab may be a particularly effective first-or second-line
agent for NMO/NMOSD. We lean towards the use of ri-
tuximab for treatment failure after initial attempts with
agents such as mycophenolate mofetile, azathioprine,
methotrexate and cyclophosphamide, as evidenced in
our present series. It is of interest that in our patients
who failed therapies before rituximab, stabilization en-
sued after changing to this monoclonal antibody. Head
to head trials of rituximab versus other promising agents
(like azathioprine, mycophenolate mofetile or metho-
trexate) for treatment of NMO/NMSD are deemed to be
difficult to perform due to the rarity of the disorders, the
long term follow up that is needed and the severe conse-
quences of treatment failure among other factors. How-
ever, controlled trials are needed.
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Our experience has shown that methotrexate is a safe
single IS therapy along with low dose corticosteroids,
which can possibly be used efficaciously in patients with
NMO/NMOSD for long-term management.
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